News
Anticoagulation prophylaxis post-knee and hip arthroplasty is recommended but commonly used thromboprophylaxis drugs have some limitations. How does oral rivaroxaban compare to subcutaneous enoxaparin ...
TIMI-11B (Thrombolysis In Myocardial Infarction 11B) 270 was a double-blind study comparing enoxaparin (bolus followed by SC injections every 12 hours for 3 to 8 days) and IV heparin (administered for ...
A new weekly injectable drug could transform the lives of more than eight million people living with Parkinson's disease, ...
argenx SE (NASDAQ:ARGX) said on Friday that it has received approval from the European Commission for its IgG Fc-antibody fragment, Vyvgart, at a 1000 mg dose, administered through a subcutaneous ...
Panelists discuss how transitioning patients from intravenous (IV) to subcutaneous (SubQ) therapies demands a coordinated, multidisciplinary approach—integrating clinical judgment, electronic medical ...
"We are pleased to announce the European Commission approval of the subcutaneous injection of VYVGART, which is co-formulated with our ENHANZE drug delivery technology for use in CIDP patients.
Panelists discuss how integrating subcutaneous (SubQ) therapies into oncology practice involves thorough economic evaluation, ...
SE (NASDAQ:ARGX) said on Friday that it has received approval from the European Commission for its IgG Fc-antibody fragment, Vyvgart's 1000 mg dose, administered through a subcutaneous injection. This ...
The company recently announced that the European Commission approved a new subcutaneous formulation of Opdivo, developed in collaboration with Halozyme’s ENHANZE technology. This approval allows the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results